BACKGROUND Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients with MBC. METHODS In this study, a total of 45 eligible patients with MBC who received eribulin in HCG Cancer Speciality Center from November 2014 to March 2016 were prospectively analyzed. Breslow (generalized Wilcoxon) survival analysis was carried out for progression-free survival and for overall survival. Patients were excluded if they had not taken treatment for 3 cycles and defaulted/expired during the treatment. RESULTS In this study, median age of patients was 52 years. A total of 27 (60%) patients had estrogen receptor and progesterone receptor (PR) positive primary tumors, whereas HER2 was overexpressed or amplified in 7 (15.6%); a triple negative subtype was recorded in 13 patients (28.9%). Regarding toxicity, 30 patients (66.67%) tolerated treatment well and 3 patients (6.67%) got anemia, 6 patients (13.3%) experienced neutropenia, and 7 (15.62%) patients had neurological toxicity. About 14 (31.1%) patients showed PR, 12 (26.7%) patients had stable disease (SD), whereas 19 (42.25%) patients showed progression disease (PD). Response evaluation at 6 cycles was possible in 18 patients and revealed that 4 (22.5%) patients showed PR, 10 (55.5%) patients had SD, whereas 4 (22.2%) patients had PD. Progression-free survival of the overall study population was 3.95 months. CONCLUSIONS Eribulin mesylate is efficacious and tolerable chemotherapy as second- and third-line treatment options for MBC.

中文翻译：

---

接受甲磺酸艾日布林作为二线或多线化疗的转移性乳腺癌患者的前瞻性分析：印度经验。

背景甲磺酸艾日布林是一种非紫杉烷类微管抑制剂，可在转移性乳腺癌（MBC）患者的蒽环类和紫杉类药物治疗后使用。本研究的目的是调查艾日布林单药治疗在接受过大量治疗的 MBC 患者中的疗效和安全性。方法本研究对2014年11月至2016年3月在HCG肿瘤专科中心接受艾日布林治疗的45例符合条件的MBC患者进行前瞻性分析。对无进展生存期和总生存期进行 Breslow（广义 Wilcoxon）生存分析。如果患者未接受治疗 3 个周期并且在治疗期间违约/过期，则患者被排除在外。结果 在这项研究中，患者的中位年龄为 52 岁。共有 27 名 (60%) 患者的原发性肿瘤为雌激素受体和孕激素受体 (PR) 阳性，而 7 名 (15.6%) 的 HER2 过度表达或扩增；13 名患者（28.9%）为三阴性亚型。毒性方面，30例（66.67%）患者耐受良好，3例（6.67%）出现贫血，6例（13.3%）出现中性粒细胞减少，7例（15.62%）出现神经毒性。大约 14 名（31.1%）患者出现 PR，12 名（26.7%）患者出现疾病稳定（SD），而 19 名（42.25%）患者出现疾病进展（PD）。18 名患者可在 6 个周期进行反应评估，结果显示 4 名（22.5%）患者出现 PR，10 名（55.5%）患者出现 SD，而 4 名（22.2%）患者出现 PD。整个研究人群的无进展生存期为 3.95 个月。